iECURE
Joseph Truitt currently serves as the CEO and Board member of iECURE Inc. Mr. Truitt previously was CEO of BioSpecifics Technologies Corp., which was recently acquired by Endo Pharmaceuticals. Prior to BioSpecifics, Mr. Truitt was CEO of Achillion Pharmaceuticals, which he joined in 2009 and held positions of increasing responsibility throughout his tenure. Mr. Truitt is Chairman of the board at Larimar Therapeutics and serves on the board of Code BioTherapeutics. Mr. Truitt served as a Captain in the United States Marine Corps. He holds an MBA from Saint Joseph’s University and a BS from LaSalle University.
iECURE
1 followers
iECURE is a gene editing company focused on developing therapies that utilize mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of liver disorders with significant unmet need. We believe our approach has the potential to replace and restore the function of a dysfunctional gene by knocking-in a healthy copy, regardless of mutation, to offer durable gene expression and long-term, potentially curative, therapeutic benefit. Our management team has extensive experience in executing global orphan drug and gene therapy clinical trials and successfully commercializing multiple products. We intend to leverage our team’s core strength in research and development strategy to identify what we believe to be the most suitable target and modality for our product candidates to address particular liver diseases. We are collaborating with the University of Pennsylvania’s Gene Therapy Program, or GTP, led by James M. Wilson, M.D., Ph.D., to utilize GTP’s world-class translational expertise and infrastructure, which has helped generate our initial pipeline of potential product candidates.